Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1987 1
1988 5
1989 5
1990 3
1991 1
1992 2
1993 4
1994 3
1995 8
1996 7
1997 6
1998 6
1999 5
2000 4
2001 8
2002 6
2003 11
2004 12
2005 2
2006 7
2007 8
2008 10
2009 11
2010 15
2011 7
2012 13
2013 18
2014 21
2015 22
2016 19
2017 22
2018 22
2019 13
2020 17
2021 25
2022 23
2023 28
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

360 results

Results by year

Filters applied: . Clear all
Page 1
WHO 2022 landscape of papillary and chromophobe renal cell carcinoma.
Lobo J, Ohashi R, Amin MB, Berney DM, Compérat EM, Cree IA, Gill AJ, Hartmann A, Menon S, Netto GJ, Raspollini MR, Rubin MA, Tan PH, Tickoo SK, Tsuzuki T, Turajlic S, Zhou M, Srigley JR, Moch H. Lobo J, et al. Histopathology. 2022 Oct;81(4):426-438. doi: 10.1111/his.14700. Epub 2022 Jun 10. Histopathology. 2022. PMID: 35596618 Review.
The WHO 2022 classification eliminated the type 1/2 papillary renal cell carcinoma (pRCC) subcategorization, given the recognition of frequent mixed tumour phenotypes and the existence of entities with a different molecular background wit …
The WHO 2022 classification eliminated the type 1/2 papillary renal cell carcinoma (pRCC) subcateg …
CAR-T cells, from principle to clinical applications.
Bourbon E, Ghesquières H, Bachy E. Bourbon E, et al. Bull Cancer. 2021 Oct;108(10S):S4-S17. doi: 10.1016/j.bulcan.2021.02.017. Bull Cancer. 2021. PMID: 34920806 Review.
The first-engineered T-cell with chimeric molecule was designed in 1993 by Israeli immunologist Zelig Eshhar. Since then, several modifications took place, including the addition of co-stimulatory domain, to further improve CAR-T cell anti-tumor potency. The first c …
The first-engineered T-cell with chimeric molecule was designed in 1993 by Israeli immunologist Zelig Eshhar. Since then, several mod …
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1alpha, HIF2alpha, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma.
Li F, Aljahdali IAM, Zhang R, Nastiuk KL, Krolewski JJ, Ling X. Li F, et al. J Exp Clin Cancer Res. 2021 Aug 12;40(1):254. doi: 10.1186/s13046-021-02026-1. J Exp Clin Cancer Res. 2021. PMID: 34384473 Free PMC article. Review.
The incidence of renal cell carcinoma (RCC) is increasing worldwide with an approximate 20% mortality rate. ...We then present our data to show the anticancer drug FL118 modulation of these protein targets and RCC cell/tumor growth. Finally, we include …
The incidence of renal cell carcinoma (RCC) is increasing worldwide with an approximate 20% mortality rate. ...We then …
Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research.
Ooi A. Ooi A. Semin Cancer Biol. 2020 Apr;61:158-166. doi: 10.1016/j.semcancer.2019.10.016. Epub 2019 Nov 2. Semin Cancer Biol. 2020. PMID: 31689495 Free PMC article. Review.
Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is an autosomal dominant hereditary cancer syndrome with incomplete penetrance. ...HLRCC patients are genetically predisposed to develop skin leiomyomas, uterine fibroids, and the aggressive kidney cancer of …
Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is an autosomal dominant hereditary cancer syndrome with incomplete pe …
The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications.
Linehan WM, Ricketts CJ. Linehan WM, et al. Nat Rev Urol. 2019 Sep;16(9):539-552. doi: 10.1038/s41585-019-0211-5. Epub 2019 Jul 5. Nat Rev Urol. 2019. PMID: 31278395 Review.
The Cancer Genome Atlas (TCGA) characterized the somatic genetic and genomic alterations in renal cell carcinoma (RCC) encompassing the major RCC histological subtypes, including clear cell RCC (ccRCC), papillary RCC (pRCC) and chromophobe RCC ( …
The Cancer Genome Atlas (TCGA) characterized the somatic genetic and genomic alterations in renal cell carcinoma (RCC) …
LAMP2A, LAMP2B and LAMP2C: similar structures, divergent roles.
Qiao L, Hu J, Qiu X, Wang C, Peng J, Zhang C, Zhang M, Lu H, Chen W. Qiao L, et al. Autophagy. 2023 Nov;19(11):2837-2852. doi: 10.1080/15548627.2023.2235196. Epub 2023 Jul 21. Autophagy. 2023. PMID: 37469132 Free PMC article. Review.
LAMP2B is required for autophagosome-lysosome fusion in cardiomyocytes and is one of the components of exosome membranes. LAMP2C is primarily implicated in a novel type of autophagy in which nucleic acids are taken up into lysosomes for degradation. ...Advances in the func …
LAMP2B is required for autophagosome-lysosome fusion in cardiomyocytes and is one of the components of exosome membranes. LAMP2C is primaril …
Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
Jin J, Xie Y, Zhang JS, Wang JQ, Dai SJ, He WF, Li SY, Ashby CR Jr, Chen ZS, He Q. Jin J, et al. Drug Resist Updat. 2023 Mar;67:100929. doi: 10.1016/j.drup.2023.100929. Epub 2023 Jan 17. Drug Resist Updat. 2023. PMID: 36739809 Free article. Review.
Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted therapy has replaced radiation therapy and chemotherapy as the main treatment option for RCC due to the lack of significant efficacy with these conventional the …
Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted therapy has replaced …
Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.
Schödel J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P, Mole DR. Schödel J, et al. Eur Urol. 2016 Apr;69(4):646-657. doi: 10.1016/j.eururo.2015.08.007. Epub 2015 Aug 19. Eur Urol. 2016. PMID: 26298207 Free PMC article. Review.
Most clear cell renal cell carcinomas (ccRCC) are associated with loss of von Hippel-Lindau tumor suppressor (pVHL) function and deregulation of hypoxia pathways. ...PATIENT SUMMARY: High levels of hypoxia-inducible transcription factors (HIF) are particularl …
Most clear cell renal cell carcinomas (ccRCC) are associated with loss of von Hippel-Lindau tumor suppressor (pVHL) fun …
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Khoja L, et al. Ann Oncol. 2017 Oct 1;28(10):2377-2385. doi: 10.1093/annonc/mdx286. Ann Oncol. 2017. PMID: 28945858 Free article. Review.
BACKGROUND: Immune checkpoint inhibitor (ICI) monoclonal antibodies (mAbs) targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) or its ligand (PD-L1) produce unique toxicity profiles. ...Comparison of irAE from the three …
BACKGROUND: Immune checkpoint inhibitor (ICI) monoclonal antibodies (mAbs) targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed …
Papillary renal cell carcinoma: current and controversial issues.
Angori S, Lobo J, Moch H. Angori S, et al. Curr Opin Urol. 2022 Jul 1;32(4):344-351. doi: 10.1097/MOU.0000000000001000. Epub 2022 Jun 9. Curr Opin Urol. 2022. PMID: 35674688 Free PMC article. Review.
PURPOSE OF THE REVIEW: Papillary renal cell carcinoma (pRCC) is the second most frequent renal cancer subtype and represents 15-20% of all RCC. ...RECENT FINDINGS: It has been 25 years ago, that pRCC was morphologically subdivided into type …
PURPOSE OF THE REVIEW: Papillary renal cell carcinoma (pRCC) is the second most frequent renal cancer sub …
360 results